BGB-A317-213

Recruiting

Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma

Beigene Study ID info

BGB-A317-213

ClinicalTrials.gov ID info

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents